If you have been reading about synthetic peptide and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-07-27. Where a claim depends on a specific study, the study is described rather than over-claimed.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide fragment | Not a full hormone |
| Molecular target | Proposed adipose tissue lipolysis | Receptor details uncertain |
| Typical research dose | Not established for clinical use | Doses vary across studies |
| Stability in solution | Limited; store cold | Avoid repeated freeze-thaw |
| Regulatory status | Not approved as a drug | Varies by country |
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
Several names appear in scientific and commercial settings. AOD9604 and AOD-9604 are development codes used interchangeably, while hGH fragment 176-191 describes the same region. The peptide includes a disulfide bond between two cysteine residues, which helps shape its three-dimensional structure. Different suppliers may provide acetate or other salt forms, and purity can vary. These differences matter because analytical tests and biological assays can respond to the specific form being studied.
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
== Pathophysiology == Cerebrospinal fluid is produced by the choroid plexus in the ventricles of the brain and contained by the dura and arachnoid layers of the meninges. The brain floats in CSF, which also transports nutrients to the brain and spinal cord. As holes form in the spinal dura mater, CSF leaks out into the surrounding space. The CSF is then absorbed into the spinal epidural venous plexus or soft tissues around the spine. Due to the sterile conditions of the soft tissues around the spine, there is no risk of meningitis.
==== Membrane filtration ==== Membrane filtration can remove suspended solids and organic components, and inorganic pollutants such heavy metals. For heavy metal removal, several forms of membrane filtration, such as ultrafiltration, nanofiltration, and reverse osmosis, can be used depending on the particle size that can be maintained. Antiscalants can help maintain membrane filtration. Some small molecules can permeate to some extent through membranes.
Usman Yusuf - professor of hematology-oncology and bone marrow transplantation, former chief executive officer of the National Health Insurance Scheme (NHIS). Bello Bako Dambatta - professor of chemistry, vice chancellor Bayero University kano. Aisha Maikudi - professor of international law, vice chancellor University of Abuja, youngest female vice-chancellor at the age of 41. Hadiza Galadanci - professor of obstetrics and gynecology at Bayero University, Kano, director of the World Bank Africa Center of Excellence for Population Health and Policy. Muhammad Yahuza Bello - professor of mathematics, 10th vice-chancellor Bayero University kano Fatima Tahir - professor of microbiology, vice-chancellor of Bauchi State University. Ibrahim Umar (physicist) - professor of physics, 3rd vice chancellor Bayero University kano. Abubakar Sani Sambo - former director-general of Energy Commission of Nigeria (ECN), former vice chancellor of Abubakar Tafawa Balewa University. Mahmud Tukur - first vice chancellor Of Bayero University Kano, former minister of commerce and industry. Aisha Mahmoud Hamman - professor in the Department of Accounting and Finance at Ahmadu Bello University, Zaria Haruna Musa - professor of chemistry, vice-chancellor Bayero University Kano. Abba Gumel - professor & The Michael and Eugenia Brin Endowed E-Nnovate Chair in Mathematics at the Department of Mathematics, University of Maryland. Fatimah Tuggar - professor of AI in Arts, University of Florida.
Sources: en.wikipedia.org
==== Persistent pulmonary hypertension ==== Persistent pulmonary hypertension (PPHN) is a serious and life-threatening, but very rare, lung condition that occurs soon after the birth of the newborn. Newborn babies with PPHN have high pressure in their lung blood vessels and are not able to get enough oxygen into their bloodstream. About 1 to 2 babies per 1000 babies born in the U.S. develop PPHN shortly after birth, and often they need intensive medical care. It is associated with about a 25% risk of significant long-term neurological deficits. A 2014 meta analysis found no increased risk of persistent pulmonary hypertension associated with exposure to SSRIs in early pregnancy and a slight increase in risk associates with exposure late in pregnancy; "an estimated 286 to 351 women would need to be treated with an SSRI in late pregnancy to result in an average of one additional case of persistent pulmonary hypertension of the newborn". A review published in 2012 reached conclusions similar to those of the 2014 study.
The term "MPR vaccine" is also used to refer to this vaccine, whereas "P" refers to parotitis which is caused by mumps. Merck MMR II is supplied freeze-dried (lyophilized) and contains live viruses. Before injection, it is reconstituted with the solvent provided. According to a review published in 2018, the GlaxoSmithKline (GSK) MMR vaccine known as Pluserix "contains the Schwarz measles virus, the Jeryl Lynn–like mumps strain, and RA27/3 rubella virus". Pluserix was introduced in Hungary in 1999. Enders' Edmonston strain has been used since 1999 in Hungary in Merck MMR II product. GSK Priorix vaccine, which uses attenuated Schwarz Measles, was introduced in Hungary in 2003.
In short, I am very far from being opposed to the reorganization of Colombia according to the experienced institutions of wise Europe. On the contrary, I would be infinitely happy and revive my strength to help in a work that can be called salvation and that can be achieved not without difficulty supported by us from England and France. With these powerful aids we would be capable of everything, without them, no. For the same reason, I reserve myself to give my definitive opinion when we know what the governments of England and France think about the aforementioned change of system and choice of dynasty." Some historians, such as Rubén Vargas Ugarte, affirm that the lack of good faith in his actions and his lack of appreciation for Peruvian chiefs and officials (which make him less than ideal from a moral point of view), together with the set of Bolívar's anti-Peruvian insults, would be the product of his "nervous breakdowns". Antonio José de Sucre, during his actions in the Secession of Upper Peru (where the independence of Upper Peru was not foreseeable by "judgment persons", if not by a regionalist oligarchy) or in the Gran Colombo-Peruvian War (of which accuses him of being excessively triumphalist and generating dishonours), in addition to proposing the fragmentation of Peru into a Republic of the north and south while ceding Arica to the Republic of Bolívar.
Sources: en.wikipedia.org
It is proposed to promote lipolysis in fat tissue, the breakdown of stored fat into fatty acids and glycerol. The detailed receptor and signaling mechanisms are not fully established.
Because it is a fragment rather than full growth hormone, it is generally described as lacking growth-promoting effects. Some studies suggest it may influence fat metabolism without the same systemic growth effects, though evidence is limited.
Human trials have measured body weight, fat mass, lean mass, lipid levels, and adverse events. Most have been small or short-term, so conclusions about long-term outcomes are limited.
AOD-9604 is a synthetic peptide fragment of human growth hormone, corresponding to amino acids 176-191. It is studied for potential effects on fat metabolism, but it is not approved as a drug in most countries. Its exact mechanism remains under investigation.